Compare Amylx Pharmaceuticals Inc (AMLX) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Global Payments Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.8 (market cap $2.64B), while Global Payments Inc trades at $84.98 (market cap $22.72B). The key difference: Global Payments Inc is far larger — about 8.6× Amylx Pharmaceuticals Inc's market cap, and Global Payments Inc pays a 1.16% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | GPN | |
|---|---|---|
Market Cap | $2.64B | $22.72B |
Sector | Health | Industrials |
52-Week High | $24.19 | $90.01 |
52-Week Low | $7.82 | $62.47 |
Enterprise Value | $2.39B | $40.87B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Global Payments (GPN) trades at $85.03, down 1.28% today, with a bullish technical signal from moving averages. Recent quarterly EPS beats and a consensus price target of $96.67 suggest upside potential, though negative net income margin and ROE highlight profitability challenges. Cash flow trends show strong operational performance, but rising debt-to-asset ratios warrant monitoring.
The outlook balances growth from Genius platform adoption against margin pressures and competitive fintech threats. Analysts are predominantly bullish, but investors should weigh earnings consistency against valuation risks and macroeconomic headwinds affecting payment volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
